Effect of Cabergoline on biochemical and anthropometric parameters of patient with Impaired Glucose metabolism (Impaired Fasting Glucose/Impaired Glucose Tolerance)
Effect of Cabergoline Vs placebo on HbA1C, HOMA-IR, HOMA-Beta, FPG, anthropometric parameters in patient with Impaired fasting glucose/Impaired glucose tolerance.
Shahid Beheshti University of Medical Sciences
70 participants
Jul 1, 2013
Interventional
Conditions
Summary
Impaired Glucose metabolism has no treatment and only life style modification could stop progression of this condition to diabetes, so we want to try effect of cabergoline in this condition to alleviate metabolic impairment and progression to diabetes.
Eligibility
Inclusion Criteria1
- Fasting Plasma Glucose (FPG): 100-110 mg/dL or/and 2 hour Plasma Glucose after Oral Glucose Tolerance Test (2hPG): 140-199 mg/dL.
Exclusion Criteria10
- severe hepatic failure (Child-Pugh scores of 10 or higher)
- history of pulmonary, pericardial, cardiac valvular, or retroperitoneal fibrotic disorders; increased risk of pleural effusion/pulmonary fibrosis
- hypersensitivity to ergot derivatives
- uncontrolled hypertension
- Diabetes
- Pregnant Women
- Lactating Women
- Major psychiatric disorders
- Recieving Medication effect prolactin secretion
- Bulimia or/and anorexia nervosa
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
addition of Cabergoline 0.5 mg oral tabletes twice weekly for 4 month or placebo in patients with prediabetes receiving a balanced diet, to to measure patient compliance to Cabergoline, tablet returned counted at the final visit, in addition to comparing thr prolactin level of every patient.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12613001121752